Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9683532 | PMC |
| http://dx.doi.org/10.1016/j.eimc.2022.10.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Artificial Intelligence Assessment of Chest Radiographs for COVID-19.
Clin Lymphoma Myeloma Leuk
November 2024
Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Background: The sensitivity of reverse-transcription polymerase chain reaction (RT-PCR) is limited for diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Chest computed tomography (CT) is reported to have high sensitivity; however, given the limited availability of chest CT during a pandemic, the assessment of more readily available imaging, such as chest radiographs, augmented by artificial intelligence may substitute for the detection of the features of coronavirus disease 2019 (COVID-19) pneumonia.
Methods: We trained a deep convolutional neural network to detect SARS-CoV-2 pneumonia using publicly available chest radiography imaging data including 8,851 normal, 6,045 pneumonia, and 200 COVID-19 pneumonia radiographs.
Comparative analysis between genotypes of adenovirus isolates from hospitalized children with acute respiratory tract infections and clinical manifestations in Wuhan, China, from June 2022 to September 2023.
Virol Sin
December 2024
Department of Laboratory Medicine, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430070, China; School of Laboratory Medicine, Hubei University of Chinese Medicine, Wuhan 430065, China. Electronic address:
Acute respiratory tract infections (ARTIs) are among the leading causes of morbidity and mortality in children worldwide. Human adenovirus (HAdV) infections are estimated to account for at least 5% of pediatric ARTIs. The circulated genotypes of HAdV and the correlation between genotype and clinical manifestations in Wuhan, China, before and after the complete relaxation of nonpharmaceutical interventions against severe acute respiratory syndrome coronavirus 2, remain unknown.
View Article and Find Full Text PDFBackground: Recent biomedical research has shown the unusual, multisystem effects of coronavirus disease 2019 in humans. One specific sequela of a primary severe acute respiratory syndrome coronavirus 2 infection is the reactivation of latent viruses in various tissues, such as Epstein-Barr virus. Epstein-Barr virus has been identified in many inflammatory gastrointestinal lesions, such as microscopic gastritides and colitides.
View Article and Find Full Text PDFEffects of two different dexamethasone dosing regimens on ventilator-free days and long-term mortality in COVID-19 patients with moderate-to-severe ARDS: the REMED randomized clinical trial.
Eur J Med Res
December 2024
Bloomsbury Institute of Intensive Care Medicine, Division of Medicine, University College London, London, UK.
Background: Dexamethasone 6 mg in patients with severe COVID-19 has been shown to decrease mortality and morbidity. The effects of higher doses of corticosteroid, that would further increase anti-inflammatory effects, are uncertain. The objective of our study was to assess the effect of 20 mg dexamethasone vs.
View Article and Find Full Text PDFBackground: Optimizing outcomes of hospitalized patients anchors on standardizing processes in medical management, interventions to reduce the risk of decompensation, and prompt intervention when a patient decompensates.
Methods: A quality improvement initiative (optimized sepsis and respiratory compromise management, reducing health care-associated infection and medication risk, swift management of the deteriorating patient, feedback on performance, and accountability) was implemented in a multistate health system. The primary outcome was risk-adjusted in-hospital mortality.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!